Dynasore: Noncompetitive Dynamin GTPase Inhibitor for Precision Endocytosis Research

Executive Summary: Dynasore (SKU A1605, APExBIO) is a cell-permeable, noncompetitive inhibitor of dynamin GTPase activity with an IC₅₀ of 15 µM in vitro, targeting the GTPase enzymes dynamin1, dynamin2, and Drp1. It blocks dynamin-dependent endocytosis, including clathrin-mediated pathways, as shown by reduced viral entry and transferrin uptake in multiple cell types (Wang et al., 2018). Dynasore is soluble in DMSO but not in water or ethanol, and its effects are reversible, making it a robust tool for dissecting vesicle trafficking and synaptic function (internal review). The compound is for research use only.

Biological Rationale

Endocytosis is essential for nutrient uptake, receptor recycling, and cellular signaling. Dynamin GTPases (dynamin1, dynamin2, Drp1) are vital for vesicle scission from plasma and organelle membranes. Noncompetitive GTPase inhibitors like Dynasore provide powerful means to interrogate these endocytic and vesicle trafficking pathways in living cells. Dysregulated endocytosis is implicated in cancer, neurodegenerative diseases, and viral infection, making dynamin GTPase signaling pathways key targets for basic and translational research (Wang et al., 2018). Dynasore's ability to rapidly and reversibly inhibit dynamin-dependent endocytosis allows for controlled mechanistic studies across diverse biological models. This extends foundational work on endocytosis to new disease models and signaling contexts (see prior mechanism overview).

Mechanism of Action of Dynasore

Dynasore acts as a noncompetitive inhibitor of dynamin GTPase activity. It binds reversibly to dynamin1, dynamin2, and Drp1, blocking GTP hydrolysis required for membrane fission during endocytosis. This inhibition disrupts the scission of clathrin-coated vesicles and other dynamin-dependent trafficking events. Dynasore does not compete with GTP for binding, distinguishing it from competitive inhibitors. Its effects are rapidly reversible upon removal, enabling precise temporal control in experimental setups (internal summary). Dynasore's selectivity for dynamin GTPases minimizes off-target effects on unrelated GTPases at working concentrations (≤80 µM).

Evidence & Benchmarks

• Dynasore inhibits dynamin-dependent endocytosis in grass carp kidney (CIK) cells, blocking clathrin-mediated viral entry at 80 µM, as shown by reduced GCRV104 infection rates (Wang et al., 2018).
• Transferrin uptake assays in HL-1 cells and neurons demonstrate reversible inhibition of endocytosis by Dynasore at 80 µM, which is restored upon compound removal (internal bench data).
• Dynasore shows an in vitro IC₅₀ of 15 µM against dynamin GTPase activity using purified protein and GTP hydrolysis assays (APExBIO product documentation).
• Dynasore does not inhibit unrelated GTPases, such as Ras or Rab family proteins, at concentrations up to 80 µM, supporting its target selectivity (internal review).
• Comparative studies with pitstop2 and chlorpromazine confirm that Dynasore’s mechanistic effect is primarily via dynamin inhibition, not clathrin or actin modulation (Wang et al., 2018).

This article extends prior translational reviews by providing current, comparative evidence for Dynasore’s selectivity and reversibility in new cell types.

Applications, Limits & Misconceptions

Dynasore has enabled advances in:

• Endocytosis research: Dissects clathrin-mediated and dynamin-dependent vesicle trafficking in mammalian and aquatic models (Wang et al., 2018).
• Synaptic vesicle endocytosis inhibition: Temporally controls vesicle recycling in neuron studies.
• Signal transduction pathway studies: Separates dynamin-mediated signaling from upstream ligand binding events.
• Cancer and neurodegenerative disease modeling: Interrogates altered endocytosis in disease-relevant cell lines (reviewed here).

For broader context, this practical workflow article details how Dynasore (A1605) improves assay reliability—a focus not covered here, as we emphasize mechanistic and comparative evidence.

Common Pitfalls or Misconceptions

• Dynasore is not effective in blocking endocytosis pathways that are dynamin-independent (e.g., caveolin- or flotillin-mediated entry) (Wang et al., 2018).
• The compound is insoluble in water and ethanol; improper solvent use leads to precipitation and loss of activity (APExBIO).
• It should not be used for diagnostic or therapeutic purposes—it is for scientific research only.
• Dynasore's GTPase inhibition is reversible and rapidly lost upon washout, so continuous exposure is required for sustained effects (internal review).
• Some cell types may require empiric titration due to variable membrane permeability or efflux activity.

Workflow Integration & Parameters

For optimal results, prepare Dynasore stock solutions in DMSO at concentrations ≥16.12 mg/mL. Warming at 37°C or mild sonication increases solubility. Store stock aliquots at -20°C for several months. Working concentrations typically range from 10–80 µM in cell culture media (final DMSO ≤0.5% v/v). For functional assays:

• Pre-treat cells for 15–30 minutes prior to endocytic challenge (e.g., transferrin uptake, viral infection).
• Washout restores endocytosis within 10–30 minutes, enabling reversibility experiments.
• Monitor for cytotoxicity in sensitive models; most lines tolerate ≤80 µM (Q&A guidance).

For further reading, the APExBIO Dynasore product page provides storage, handling, and MSDS details.

Conclusion & Outlook

Dynasore (A1605, APExBIO) remains a cornerstone noncompetitive dynamin GTPase inhibitor for endocytosis and vesicle trafficking studies. Its validated selectivity, reversibility, and compatibility with diverse models enable rigorous mechanistic and translational research. Future directions include combinatorial use with genetic perturbations and application to emerging disease models. For robust, reproducible dissection of endocytic pathways, Dynasore offers proven performance and workflow flexibility (Wang et al., 2018).